BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28958806)

  • 1. Role of tangeretin as a potential bioavailability enhancer for silybin: Pharmacokinetic and pharmacological studies.
    Yuan ZW; Li YZ; Liu ZQ; Feng SL; Zhou H; Liu CX; Liu L; Xie Y
    Pharmacol Res; 2018 Feb; 128():153-166. PubMed ID: 28958806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperine enhances the bioavailability of silybin via inhibition of efflux transporters BCRP and MRP2.
    Bi X; Yuan Z; Qu B; Zhou H; Liu Z; Xie Y
    Phytomedicine; 2019 Feb; 54():98-108. PubMed ID: 30668388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2.
    Xu P; Zhou H; Li YZ; Yuan ZW; Liu CX; Liu L; Xie Y
    Front Pharmacol; 2018; 9():1115. PubMed ID: 30416442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP.
    Pan L; Zeng K; Wang X; Bi H; Hu H; Huang M; Lou Y; Zeng S
    Int J Pharm; 2015 Dec; 496(2):440-7. PubMed ID: 26475967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
    Xiao L; Yi T; Chen M; Lam CW; Zhou H
    Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated system exposures of baicalin after combinatory oral administration of rhein and baicalin: Mainly related to breast cancer resistance protein (ABCG2), not UDP-glucuronosyltransferases.
    Zhang Y; Zhang M; Hu G; Zhang Z; Song R
    J Ethnopharmacol; 2020 Mar; 250():112528. PubMed ID: 31884038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
    Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
    J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
    Fleisher B; Unum J; Shao J; An G
    J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
    Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
    J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.
    Li L; Yao QQ; Xu SY; Hu HH; Shen Q; Tian Y; Pan LY; Zhou H; Jiang HD; Lu C; Yu LS; Zeng S
    Eur J Pharm Biopharm; 2014 Nov; 88(3):759-67. PubMed ID: 24980806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP.
    Ge S; Yin T; Xu B; Gao S; Hu M
    Pharm Res; 2016 Mar; 33(3):590-602. PubMed ID: 26502886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.
    Li X; Zhong K; Guo Z; Zhong D; Chen X
    Drug Metab Dispos; 2015 Nov; 43(11):1751-9. PubMed ID: 26276582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism, Transport and Drug-Drug Interactions of Silymarin.
    Xie Y; Zhang D; Zhang J; Yuan J
    Molecules; 2019 Oct; 24(20):. PubMed ID: 31615114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
    Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saturation of multidrug-resistant protein 2 (mrp2/abcc2)-mediated hepatobiliary secretion: nonlinear pharmacokinetics of a heterocyclic compound in rats after intravenous bolus administration.
    Hu Y; Sampson KE; Heyde BR; Mandrell KM; Li N; Zutshi A; Lai Y
    Drug Metab Dispos; 2009 Apr; 37(4):841-6. PubMed ID: 19139164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
    Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinational applicaton of silybin and tangeretin attenuates the progression of non-alcoholic steatohepatitis (NASH) in mice via modulating lipid metabolism.
    Suguro R; Pang XC; Yuan ZW; Chen SY; Zhu YZ; Xie Y
    Pharmacol Res; 2020 Jan; 151():104519. PubMed ID: 31706011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin.
    Hirano M; Maeda K; Matsushima S; Nozaki Y; Kusuhara H; Sugiyama Y
    Mol Pharmacol; 2005 Sep; 68(3):800-7. PubMed ID: 15955871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine.
    Ceckova M; Reznicek J; Ptackova Z; Cerveny L; Müller F; Kacerovsky M; Fromm MF; Glazier JD; Staud F
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5563-72. PubMed ID: 27401571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K; Sane R; Podila L; Taub ME
    J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.